<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589977</url>
  </required_header>
  <id_info>
    <org_study_id>141686</org_study_id>
    <nct_id>NCT02589977</nct_id>
  </id_info>
  <brief_title>Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF</brief_title>
  <acronym>HFpEF-PRoF</acronym>
  <official_title>Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marvin W. Kronenberg, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unlike heart failure with reduced ejection fraction (HFrEF) where several medicines and&#xD;
      devices have been demonstrated to reduce mortality, no such therapies have been identified in&#xD;
      HFpEF. This may be in part due to incomplete understanding of the underlying mechanisms of&#xD;
      HFpEF.&#xD;
&#xD;
      Recently, impaired myocardial blood flow, reduced myocardial energy utilization, and&#xD;
      increased myocardial fibrosis have been postulated to play important pathophysiologic roles&#xD;
      in HFpEF. The investigators and others have demonstrated that HFrEF may be associated with&#xD;
      altered myocardial energy utilization and &quot;energy starvation.&quot; However, there are limited&#xD;
      data regarding &quot;energy starvation&quot; in HFpEF and the relationships between myocardial blood&#xD;
      flow, energy utilization, and fibrosis in HFpEF are largely unknown. Therefore, the purposes&#xD;
      of this study are to use non-invasive cardiac imaging techniques to describe cardiac&#xD;
      structure, function, blood flow, energetics, and fibrosis, and the relationships between&#xD;
      these in order to better understand underlying mechanisms in HFpEF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that HFpEF is associated with reductions in myocardial blood&#xD;
      flow and energy utilization and increased myocardial fibrosis as compared to age and gender&#xD;
      matched hypertensive and healthy controls. The investigators will test their hypotheses by&#xD;
      comparing measurements of myocardial blood flow, energy utilization, and fibrosis between&#xD;
      three subject groups (HFpEF vs hypertension vs healthy). Myocardial blood flow will be&#xD;
      quantitated from nitrogen (N)13-Ammonia positron emission tomography (PET) and gadolinium&#xD;
      enhanced cardiac magnetic resonance (CMR) imaging, both at rest and stress following coronary&#xD;
      vasodilation with regadenoson. Myocardial energy utilization will be quantified with&#xD;
      11C-acetate PET imaging and myocardial fibrosis will be assessed with gadolinium enhanced CMR&#xD;
      and alterations in myocardial T1. Echocardiography will be utilized to quantify cardiac&#xD;
      diastolic function.&#xD;
&#xD;
      It is anticipated that the results of this proposed study will provide a foundation that will&#xD;
      inform future studies aimed at identifying novel preventive or therapeutic agents in HFpEF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">January 21, 2020</completion_date>
  <primary_completion_date type="Actual">January 21, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Flow Reserve</measure>
    <time_frame>Baseline study visit</time_frame>
    <description>Rest and regadenoson stress coronary flow reserve by ammonia PET. Coronary flow calculated at rest and again at stress with coronary flow reserve calculated as the ratio of stress to rest coronary flow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Perfusion Reserve by CMR in Each Study Group.</measure>
    <time_frame>Baseline study visit.</time_frame>
    <description>Myocardial perfusion reserve by CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular Volume (ECV) by CMR in Each Study Group</measure>
    <time_frame>Baseline study visit</time_frame>
    <description>Extracellular volume (ECV) by CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.</measure>
    <time_frame>Baseline study visit</time_frame>
    <description>Oxidative metabolism (Kmono/rate pressure product) by PET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E/e' by Echo in Each Study Group.</measure>
    <time_frame>Baseline study visit</time_frame>
    <description>E/e' by echo. E is the transmitral peak velocity in early diastole. e' is the early diastolic tissue Doppler velocity average between the septal and lateral mitral annulus. E/e' is the ratio of these two values.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Diastolic Heart Failure</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>normal participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertensive participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFpEF patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regadenoson</intervention_name>
    <description>evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
    <arm_group_label>HFpEF patients</arm_group_label>
    <arm_group_label>hypertensive participants</arm_group_label>
    <arm_group_label>normal participants</arm_group_label>
    <other_name>positron emission tomography</other_name>
    <other_name>echocardiography</other_name>
    <other_name>cardiac magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        ALL&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  estimated glomerular filtration rate (eGFR) &gt; 60 ml/min&#xD;
&#xD;
          -  preserved left ventricular ejection fraction (&gt;= 50%) on echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  coronary artery disease&#xD;
&#xD;
          -  diabetes mellitus&#xD;
&#xD;
          -  contraindications to cardiac magnetic resonance imaging (CMR)&#xD;
&#xD;
          -  weight &gt;350 lbs&#xD;
&#xD;
          -  inability to lie flat for imaging&#xD;
&#xD;
          -  anemia&#xD;
&#xD;
          -  contraindications to regadenoson or aminophylline&#xD;
&#xD;
        HEALTHY&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  normal cardiac structure and function on echocardiography&#xD;
&#xD;
          -  BP &lt; 140/90&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  known cardiovascular disease, cardiac risk factors or use of cardiac medications&#xD;
&#xD;
        HYPERTENSIVE&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  history of BP &gt;140/90&#xD;
&#xD;
          -  1 or more antihypertensive medications&#xD;
&#xD;
          -  LV ejection fraction (LVEF) at least 50%&#xD;
&#xD;
          -  current BP &lt; 160/90&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  known cardiovascular disease or risk factors aside from hypertension or use of cardiac&#xD;
             medications&#xD;
&#xD;
        HFpEF&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  physician-confirmed diagnosis of HF&#xD;
&#xD;
          -  symptomatic HF&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
          -  elevated LV filling pressure by catheterization, echocardiographic criteria or&#xD;
             B-type-natriuretic peptide &gt; 100&#xD;
&#xD;
          -  current BP &lt; 160/90&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  prior history of LVEF below 50%&#xD;
&#xD;
          -  acute decompensated HF&#xD;
&#xD;
          -  moderate or greater valvular disease&#xD;
&#xD;
          -  significant cardiac arrhythmias&#xD;
&#xD;
          -  pericardial disease&#xD;
&#xD;
          -  congenital heart disease&#xD;
&#xD;
          -  primary pulmonary hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin W Kronenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bell SP, Adkisson DW, Ooi H, Sawyer DB, Lawson MA, Kronenberg MW. Impairment of subendocardial perfusion reserve and oxidative metabolism in nonischemic dilated cardiomyopathy. J Card Fail. 2013 Dec;19(12):802-10. doi: 10.1016/j.cardfail.2013.10.010. Epub 2013 Oct 29.</citation>
    <PMID>24331202</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta DK, Shah AM, Castagno D, Takeuchi M, Loehr LR, Fox ER, Butler KR, Mosley TH, Kitzman DW, Solomon SD. Heart failure with preserved ejection fraction in African Americans: The ARIC (Atherosclerosis Risk In Communities) study. JACC Heart Fail. 2013 Apr;1(2):156-63.</citation>
    <PMID>23671819</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <results_first_submitted>December 23, 2020</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Marvin W. Kronenberg, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine and Radiology</investigator_title>
  </responsible_party>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>positron-emission tomography</keyword>
  <keyword>echocardiography</keyword>
  <keyword>myocardial blood flow</keyword>
  <keyword>energy metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02589977/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Participants</title>
          <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
        <group group_id="P2">
          <title>Hypertensive Participants</title>
          <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
        <group group_id="P3">
          <title>HFpEF Patients</title>
          <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>These are the people who attended baseline visit.</population>
      <group_list>
        <group group_id="B1">
          <title>Normal Participants</title>
          <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
        <group group_id="B2">
          <title>Hypertensive Participants</title>
          <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
        <group group_id="B3">
          <title>HFpEF Patients</title>
          <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="54" upper_limit="62"/>
                    <measurement group_id="B2" value="58" lower_limit="54" upper_limit="65"/>
                    <measurement group_id="B3" value="69" lower_limit="62" upper_limit="73"/>
                    <measurement group_id="B4" value="58" lower_limit="55" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" lower_limit="22.6" upper_limit="28.7"/>
                    <measurement group_id="B2" value="30.1" lower_limit="27.8" upper_limit="35.7"/>
                    <measurement group_id="B3" value="34.2" lower_limit="29.9" upper_limit="37.8"/>
                    <measurement group_id="B4" value="29.7" lower_limit="25.6" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coronary Flow Reserve</title>
        <description>Rest and regadenoson stress coronary flow reserve by ammonia PET. Coronary flow calculated at rest and again at stress with coronary flow reserve calculated as the ratio of stress to rest coronary flow.</description>
        <time_frame>Baseline study visit</time_frame>
        <population>Incomplete data for 18 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O2">
            <title>Hypertensive Participants</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O3">
            <title>HFpEF Patients</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Flow Reserve</title>
          <description>Rest and regadenoson stress coronary flow reserve by ammonia PET. Coronary flow calculated at rest and again at stress with coronary flow reserve calculated as the ratio of stress to rest coronary flow.</description>
          <population>Incomplete data for 18 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" lower_limit="2.34" upper_limit="2.85"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.56" upper_limit="3.11"/>
                    <measurement group_id="O3" value="2.06" lower_limit="1.96" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Perfusion Reserve by CMR in Each Study Group.</title>
        <description>Myocardial perfusion reserve by CMR.</description>
        <time_frame>Baseline study visit.</time_frame>
        <population>Incomplete data for 10 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O2">
            <title>Hypertensive Participants</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O3">
            <title>HFpEF Patients</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Perfusion Reserve by CMR in Each Study Group.</title>
          <description>Myocardial perfusion reserve by CMR.</description>
          <population>Incomplete data for 10 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.81" upper_limit="2.64"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.44" upper_limit="2.59"/>
                    <measurement group_id="O3" value="1.29" lower_limit="1.11" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extracellular Volume (ECV) by CMR in Each Study Group</title>
        <description>Extracellular volume (ECV) by CMR.</description>
        <time_frame>Baseline study visit</time_frame>
        <population>Incomplete data for 9 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O2">
            <title>Hypertensive Participants</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O3">
            <title>HFpEF Patients</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
        </group_list>
        <measure>
          <title>Extracellular Volume (ECV) by CMR in Each Study Group</title>
          <description>Extracellular volume (ECV) by CMR.</description>
          <population>Incomplete data for 9 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
          <units>percent ECV</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" lower_limit="28.5" upper_limit="34.2"/>
                    <measurement group_id="O2" value="29.2" lower_limit="27.4" upper_limit="33.1"/>
                    <measurement group_id="O3" value="30.9" lower_limit="29.4" upper_limit="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.</title>
        <description>Oxidative metabolism (Kmono/rate pressure product) by PET.</description>
        <time_frame>Baseline study visit</time_frame>
        <population>Incomplete data for 4 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O2">
            <title>Hypertensive Participants</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O3">
            <title>HFpEF Patients</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Metabolism (Kmono/Rate Pressure Product) by PET in Each Study Group.</title>
          <description>Oxidative metabolism (Kmono/rate pressure product) by PET.</description>
          <population>Incomplete data for 4 because of either inability to complete scan OR scan quality not adequate for analysis.</population>
          <units>min-1/(beats/min x mmhg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.10" upper_limit="0.13"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.07" upper_limit="0.11"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.09" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>E/e' by Echo in Each Study Group.</title>
        <description>E/e' by echo. E is the transmitral peak velocity in early diastole. e' is the early diastolic tissue Doppler velocity average between the septal and lateral mitral annulus. E/e' is the ratio of these two values.</description>
        <time_frame>Baseline study visit</time_frame>
        <population>We were able to collect data on all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O2">
            <title>Hypertensive Participants</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
          <group group_id="O3">
            <title>HFpEF Patients</title>
            <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
          </group>
        </group_list>
        <measure>
          <title>E/e' by Echo in Each Study Group.</title>
          <description>E/e' by echo. E is the transmitral peak velocity in early diastole. e' is the early diastolic tissue Doppler velocity average between the septal and lateral mitral annulus. E/e' is the ratio of these two values.</description>
          <population>We were able to collect data on all participants who completed the study.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="6.4" upper_limit="9.0"/>
                    <measurement group_id="O2" value="8.2" lower_limit="7.2" upper_limit="9.4"/>
                    <measurement group_id="O3" value="13.0" lower_limit="10.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This is a cross sectional study. Subjects were followed for adverse events between screening/enrollment to one day following completion of the cardiac imaging study visit. Because this was not a longitudinal study with serial measurements of the end points the time between enrollment and cross sectional cardiac imaging study visit was variable for each subject in accordance with the study protocol. All subjects completed study procedures within thirteen months of enrollment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Participants</title>
          <description>No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
        <group group_id="E2">
          <title>Hypertensive Participants</title>
          <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
        <group group_id="E3">
          <title>HFpEF Patients</title>
          <description>No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) &gt;60.&#xD;
Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism.&#xD;
regadenoson: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marvin Kronenberg, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-322-2318</phone>
      <email>marvin.w.kronenberg@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

